Octagos Health secures $43m in Series B to enhance AI-driven cardiac care

Octagos Health, a trailblazer in AI-driven cardiac device monitoring, has successfully raised over $43 million in a Series B funding round. The investment was spearheaded by Morgan Stanley Expansion Capital and saw significant contributions from Mucker Capital along with other strategic investors. This infusion of capital is set to accelerate Octagos Health’s innovative mission to revolutionize cardiac care through artificial intelligence, enhancing patient monitoring and healthcare outcomes.

Headquartered in Houston, Texas, Octagos Health has developed Atlas AI, a cutting-edge platform that leverages artificial intelligence to offer continuous monitoring and detailed analysis for patients with cardiac devices like pacemakers, defibrillators, and consumer wearables. This technology not only improves accuracy in detecting clinically significant events but also streamlines physician workflows and boosts the efficacy of healthcare delivery. The platform’s integration capabilities with electronic health records (EHR) and its customizable reporting tools have made it a favored choice among cardiology practices.

Dr. Shanti Bansal, a cardiologist and the CEO of Octagos Health, emphasized the transformative impact of the funding: “With this Series B funding, we aim to expand our reach across the US and delve into other vital areas of cardiac care. Our goal is to develop a comprehensive AI-based clinical decision support engine that enhances patient care and clinic operations. We are excited about our partnership with Morgan Stanley Expansion Capital and the ongoing support from Mucker Capital.”

The investment will facilitate further enhancements to the Atlas AI platform, including the expansion of the commercial team and scaling of operations. Octagos Health stands out as the only company currently enabling cardiology practices to transition their historical data from older software systems to a fully integrated EHR solution. This capability is coupled with customized reporting, bolstered by analytics that support both patient and practice decision-making.

Melissa Daniels, Managing Director at Morgan Stanley Expansion Capital, expressed enthusiasm about the partnership, stating, “Octagos Health has shown remarkable growth and innovation in a crucial sector of healthcare. Their integrated software and services significantly refine patient care and simplify the cardiac monitoring process for healthcare providers.”

Will Hsu, Co-Founder and Partner at Mucker Capital, highlighted the potential for Octagos Health to disrupt the market with its AI-driven solutions: “This funding will enable Octagos Health to incorporate additional data sources from various diagnostic and consumer devices, further enhancing their distinctive offerings in the market.”

Octagos Health is poised to redefine cardiac care with its AI-driven solutions, improving patient outcomes and supporting healthcare providers with advanced technology and comprehensive monitoring services. The company’s continuous monitoring and analytical capabilities make it an indispensable tool in modern healthcare institutions.

The strategic infusion of capital into Octagos Health not only accelerates the potential of AI in cardiac care but also sets a new standard in patient monitoring and data-driven healthcare.